Wenjian Zhu

Wenjian Zhu

Auto-generated profile, based on publicly available information

Wenjian Zhu

Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2025 in JMIR Cancer
Verified
Journal Article
Open access
TGTianhao Guo
Tianhao Guo
TZTingting Zhou
Tingting Zhou
WZWenjie Zhu
Wenjie Zhu
YYYumo Yuan
Yumo Yuan
YHYifan Hui
Yifan Hui
XWxiaoyu Wu
xiaoyu Wu
Background: Effective prevention and treatment are urgently needed, since gastric cancer (GC) poses a grave threat to the health and well-being of patients. The 5 East Asian countries (China, Japan, North Korea, South Korea, and Mongolia) represent one of the most significant regions globally in terms of GC burden. Objective: The goal of this study is to examine the patterns and trends of GC across 5 East Asian countries between 1990 and 2021. Methods: We retrieved data from the Global Burden of Disease Study (GBD) 2021 regarding the prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) associated with GC in 5 East Asian countries from 1990 to 2021. We further assessed the burden of GC according to age and sex. We used decomposition analysis to examine the changes in the number of new cases, patients, and deaths related to GC. We also used Joinpoint (Joinpoint Regression Program, Version 5.1.0) and age-period-cohort analysis methods to interpret the epidemiological characteristics of GC. Autoregressive integrated moving average model (ARIMA) and Bayesian age-period-cohort (BAPC) prediction models were used to forecast the GC burden by 2036. Results: Among the 5 East Asian countries, China recorded the highest incidence, prevalence, death, YLLs, YLDs, and DALYs in both 1990 and 2021. From 1990 to 2021, the age-standardized rates for prevalence, mortality, incidence, YLDs, YLLs, and DALYs across the 5 East Asian countries showed an overall decline, though they remained higher than the global average. In all 5 East Asian countries, individuals aged 65 years and older consistently exhibited the highest rates for prevalence, incidence, mortality, YLDs, YLLs, and DALYs. The prevalence rate in South Korea, the incidence rate in North Korea and Mongolia, and the mortality rate in China are influenced by aging, surpassing the global aging average. Conclusions: The disease burden of GC in the 5 East Asian countries has consistently ranked high over the past 3 decades, particularly among the older individuals. The burden of GC in the 5 East Asian countries is expected to present a major public health challenge, primarily driven by the large population size and the aging demographic.

30 September 2025 in Annals of Medicine
Verified
Journal Article
Open access
TGTianhao Guo
Tianhao Guo
WZWenjian Zhu
Wenjian Zhu
GZGuangyuan Zhang
Guangyuan Zhang
YHYifan Hui
Yifan Hui
YYYumo Yuan
Yumo Yuan
XWxiaoyu Wu
xiaoyu Wu
Colorectal cancer (CRC) is a leading global cause of cancer morbidity and mortality, yet how its burden has shifted during rapid demographic and lifestyle change in East Asia remains poorly characterized. This study fills that gap by examining long‑term trends and drivers of CRC burden in the selected East Asian countries-China, Japan, North Korea, South Korea, and Mongolia-between 1990 and 2021, and by projecting future burden through 2036. We obtained data from the Global Burden of Disease (GBD) Study 2021 on CRC-related prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) in the selected countries, further assessed by age and sex. We quantified contributions of population growth, aging and epidemiological change via decomposition analysis, characterized temporal trends with Joinpoint and age-period-cohort analysis, and generated forecasts to 2036 using Autoregressive Integrated Moving Average and Bayesian age-period-cohort approaches. Although absolute CRC burden rose across the region-driven largely by population aging-with China exhibiting the highest numbers and Japan exhibiting the highest age‑standardized rates. Older adults bore the greatest share of burden. Decomposition and modeling indicate that demographic shifts have been the predominant force behind increasing CRC counts, and projected trends suggest the regional burden will remain substantial without targeted action. This study provides novel, region‑specific evidence that demographic aging is the principal driver of rising CRC burden in East Asia. The findings highlight an urgent need for tailored prevention, screening and resource planning focused on aging populations to alter the projected trajectory.

7 December 2025 in Cancer Medicine
Verified
Journal Article
Open access
TGTianhao Guo
Tianhao Guo
WZWenjian Zhu
Wenjian Zhu
YHYifan Hui
Yifan Hui
YWYuhan Wang
Yuhan Wang
TZTingting Zhou
Tingting Zhou
HCHaibo Cheng
Haibo Cheng
Background: Pancreatic cancer (PC) presents a significant challenge for prevention and treatment, posing a serious threat to the health and lives of patients. The five East Asian countries (China, Japan, North Korea, South Korea, and Mongolia) represent one of the most significant regions globally in terms of PC burden. Methods: We retrieved data from the Global Burden of Disease (GBD) Study 2021 regarding the prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability‐adjusted life years (DALYs) associated with PC in these five East Asian countries from 1990 to 2021. We employed joinpoint, age‐period‐cohort (APC), and decomposition analysis methods to assess the epidemiological characteristics of PC. To project the future burden of PC through 2036, we applied two prediction models: Autoregressive Integrated Moving Average (ARIMA) and Bayesian age‐period‐cohort (BAPC) models. Results: China recorded the highest incidence, prevalence, mortality, YLLs, YLDs, and DALYs among the five East Asian countries in both 1990 and 2021. Japan exhibited the highest age‐standardized incidence rate (ASIR), age‐standardized mortality rate (ASMR), age‐standardized prevalence rate (ASPR), and age‐standardized YLDs rate in both 1990 and 2021. Mongolia experienced significant increases in the number and rates of incidence, prevalence, death, YLLs, YLDs, and DALYs from 1990 to 2021. The age group with the highest prevalence, incidence, mortality, YLDs, YLLs, and DALYs rates across the five East Asian countries was consistently those aged 70 and older. The incidence rate across the five countries is influenced by aging populations, surpassing global averages. Projections for 2030 and 2036 suggest that Japan will have the highest ASPR (13.23 in 2030 and 13.85 in 2036), ASIR (12.14 in 2030 and 12.53 in 2036), and ASMR (10.97 in 2030 and 11.39 in 2036) among the countries. Conclusion: The disease burden of PC in the five East Asian countries has steadily increased over the past three decades, particularly among older adults due to population aging.

29 April 2025 in Thoracic Cancer
Verified
Journal Article
Open access
TGTianhao Guo
Tianhao Guo
YYYumo Yuan
Yumo Yuan
TZTingting Zhou
Tingting Zhou
YHYifan Hui
Yifan Hui
YWYuhan Wang
Yuhan Wang
HCHaibo Cheng
Haibo Cheng
Background: In 2022, esophageal cancer (EC) was the eleventh most frequently diagnosed cancer and the seventh leading cause of cancer‐related deaths worldwide. Nonetheless, the prevalence and burden of EC in Asian countries have been little studied. This study investigated the prevalence, incidence, and burden of EC in five East Asian countries from 1990 to 2021.Methods: We retrieved data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 on the prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability‐adjusted life years (DALYs) associated with EC in five East Asian countries from 1990 to 2021. The epidemiological characteristics of EC were analyzed by joinpoint regression, age‐period‐cohort analysis, and decomposition analysis. The burden of EC until 2036 was estimated using autoregressive integrated moving average and Bayesian age‐period‐cohort models.Results: Among these East Asian countries, China had the highest incidence, prevalence, mortality rates, YLLs, YLDs, and DALYs in 1990 and 2021. China and Mongolia exhibited the highest age‐standardized incidence rate, age‐standardized mortality rate, age‐standardized prevalence rate, age‐standardized YLDs rate, age‐standardized YLLs rate, and age‐standardized DALYs rate from 1990 to 2036. The age group with the highest prevalence rate, incidence rate, mortality rate, YLDs rate, YLLs rate, and DALYs rate in these countries was ≥ 55 years. The prevalence and incidence rates in the five countries were influenced by aging and were higher than the global average.Conclusions: The burden of EC in five East Asian countries was high over the past three decades, particularly among older adults. EC is a significant public health problem in these countries, particularly because of the large population base and aging demographics.

22 January 2025 in Immunotherapy
Verified
Journal Article
Closed access
TGTianhao Guo
Tianhao Guo
YHYifan Hui
Yifan Hui
WZWenjian Zhu
Wenjian Zhu
FKFei Ke
Fei Ke
TZTingting Zhou
Tingting Zhou
HCHaibo Cheng
Haibo Cheng
The annual rise in gastrointestinal cancer cases is evident, yet the occurrence of multiple primary malignancies remains comparatively uncommon. In recent years, immunotherapy has swiftly emerged as the leading treatment for several solid tumors, including gastrointestinal cancers. Single treatments might be ineffective, necessitating the need for comprehensive integrative medicine. This study reports a case of multiple cancers, including colorectal and gastric cancers. Diverse systemic treatments, like capecitabine, the combination of capecitabine and paclitaxel liposome, as well as capecitabine with toripalimab, were unsuccessful. Nevertheless, prolonged survival was attained through anti-PD-1 immunotherapy complemented by alternative medicine approaches. The patient has exceeded a 35-month survival post-initial diagnosis and 20-month survival since the subsequent diagnosis, markedly surpassing the prognosis often associated with advanced-stage multiple cancers. In summary, this case underscores the potential effectiveness of a holistic, integrative medical approach in managing advanced multiple malignancies amid drug resistance and disease progression.